MedPath

FDA Approves First Gene Therapy, Vijuvek, for Rare Skin Disease Epidermolysis Bullosa

• The FDA has approved Vijuvek, a topical gene therapy developed by Krystal Biotech, as the first treatment of its kind for epidermolysis bullosa (EB). • Clinical trials demonstrated Vijuvek's effectiveness in healing wounds and preventing new blisters in patients with EB, offering a significant improvement in their quality of life. • The therapy, while promising, comes with a high annual cost of up to $500,000, raising concerns about accessibility and affordability for patients. • Vijuvek offers hope for increased mobility and independence for individuals with EB, potentially transforming the lives of those affected by this debilitating condition.

The FDA has approved Vijuvek, a topical gene therapy developed by Krystal Biotech, marking the first treatment of its kind for the rare genetic skin disease epidermolysis bullosa (EB). This approval offers new hope for patients like 15-year-old Rafi Kopelan, who suffers from severe pain and blistering due to EB.

Clinical Trial Success

Clinical trials have demonstrated the effectiveness of Vijuvek in healing wounds and preventing new blisters in individuals with EB. The gene therapy works by delivering functional copies of the COL7A1 gene directly to the patient's skin, enabling the production of collagen VII, a protein essential for skin integrity that is deficient in EB patients. According to Rafi's father, Brett Kopelan, executive director of DEBRA of America, the treatment offers a "very strong chance at a meaningful independent life" for those affected.

Impact on Patients

Rafi, who participated in the trials, expressed excitement about the approval, stating, "It means that I will be in a lot less pain." She anticipates a better lifestyle with improved sleep and increased mobility. The therapy's ability to heal wounds is expected to significantly reduce pain and itching, allowing patients to lead more active and independent lives.

Cost Concerns

Despite the promising results, the high cost of Vijuvek, estimated at up to $500,000 per year, raises concerns about accessibility. Brett Kopelan noted that while Rafi is covered by Medicaid in Colorado, ensuring access for all patients will be a challenge. The financial burden may limit the availability of this potentially life-changing treatment for many individuals with EB.

Future Outlook

With the FDA approval, Vijuvek is expected to become available as early as July. This development represents a significant advancement in the treatment of EB, offering hope for improved quality of life and increased independence for those living with this challenging condition. Rafi, who aspires to become an early education teacher, exemplifies the potential for individuals with EB to overcome the limitations imposed by the disease and pursue their dreams.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

ViGeneron's VG901 Receives FDA Rare Pediatric Disease Designation and Advances to Dose Escalation in Phase 1b Trial for Retinitis Pigmentosa

The FDA granted Rare Pediatric Disease Designation to ViGeneron's VG901, a gene therapy for retinitis pigmentosa caused by CNGA1 gene mutations, highlighting the urgent need for new treatments.
VG901 leverages ViGeneron's vgAAV capsid to deliver the functional CNGA1 gene to retinal photoreceptor cells via intravitreal injection, offering a less invasive approach.

FDA Grants Orphan Drug Designation to EXG110 Gene Therapy for Fabry Disease

The FDA has granted orphan drug designation to EXG110, a novel gene therapy developed by Exegenesis Bio for Fabry disease.
EXG110 is designed as a one-time treatment to deliver a genetic payload directly to liver and heart cells, potentially improving efficacy and safety.

Enveda Therapeutics Secures $130M to Advance AI-Driven Eczema Treatment

Enveda Therapeutics has secured $130 million in funding to advance its AI-driven drug discovery platform and clinical programs.
The funding will support the development of Enveda's lead candidate, an eczema treatment currently in Phase I clinical trials, and a drug for inflammatory bowel diseases.

FDA Approves Kebilidi, First Brain-Delivered Gene Therapy for AADC Deficiency

The FDA has approved Kebilidi (eladocagene exuparvovec-tneq), a gene therapy for AADC deficiency, marking the first brain-delivered gene therapy approved in the U.S.
Kebilidi is administered directly into the brain and replaces the mutated DDC gene with a functional version, restoring dopamine and serotonin production in both adults and children.

FDA Approves PTC Therapeutics' Kebilidi, First Gene Therapy Dosed Directly into the Brain

The FDA has approved Kebilidi (eladocagene exuparvovec), a gene therapy by PTC Therapeutics, for aromatic L-amino acid decarboxylase (AADC) deficiency, a rare genetic disorder.
Kebilidi is the first gene therapy approved in the U.S. that involves direct administration into the brain, offering a novel approach to treating AADC deficiency.

FDA Approves Kebilidi, First Gene Therapy Directly Administered to the Brain for AADC Deficiency

The FDA has granted accelerated approval to Kebilidi (eladocagene exuparvovec-tneq), a gene therapy for both children and adults with AADC deficiency, a rare genetic disorder.
Kebilidi, developed by PTC Therapeutics, is the first gene therapy approved in the U.S. that is directly administered to the brain via a stereotactic surgical procedure.

FDA Approves Eladocagene Exuparvovec-Tneq (Kebilidi) for AADC Deficiency

The FDA has approved eladocagene exuparvovec-tneq (Kebilidi) as the first gene therapy for both adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency.
Approval was based on a clinical trial of 13 pediatric patients, where 8 of 12 treated individuals showed improved gross motor function compared to untreated individuals.

FDA Approves PTC Therapeutics' Kebilidi, First Direct-to-Brain Gene Therapy

The FDA has approved PTC Therapeutics' Kebilidi (eladocagene exuparvovec-tneq) for aromatic L-amino acid decarboxylase (AADC) deficiency, a rare genetic disorder.
Kebilidi is the first gene therapy approved by the FDA that is administered directly into the brain, specifically targeting the putamen region.

FDA Approves Sunlenca (Lenacapavir), a First-in-Class HIV-1 Capsid Inhibitor

The FDA has approved Sunlenca (lenacapavir) as the first capsid inhibitor for heavily treatment-experienced adults with multi-drug resistant HIV-1 infection.
Sunlenca, administered twice-yearly, offers a novel mechanism of action by blocking the HIV-1 virus's protein shell, addressing a critical unmet need.

FDA Approves Krystal Biotech's Vyjuvek, a Topical Gene Therapy for Dystrophic Epidermolysis Bullosa

The FDA has approved Vyjuvek, Krystal Biotech's topical gene therapy, marking the first treatment of its kind for dystrophic epidermolysis bullosa.
Vyjuvek is approved for patients aged six months and older with either recessive or dominant forms of dystrophic epidermolysis bullosa.

Reference News

[1]
FDA approves first gene therapy for rare skin disease, but costs are outrageous - CBS Colorado
cbsnews.com · May 26, 2023

FDA approves Vijuvek, the first gene therapy for EB, offering hope to patients like Rafi Kopelan. Despite its high cost,...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy